Detalles de la búsqueda
1.
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Lancet
; 402(10403): 693-704, 2023 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385279
2.
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Diabetes Obes Metab
; 23(12): 2752-2762, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463425
3.
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
Diabetes Obes Metab
; 22(5): 779-787, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31903697
4.
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
Diabetes Obes Metab
; 22(5): 873-878, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31903724
5.
The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials.
Pediatr Diabetes
; 20(3): 314-320, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30666772
6.
The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(7): 1585-1592, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29451706
7.
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab
; 25(4): 1130-1135, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36562481
8.
Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
Pediatr Diabetes
; 17(8): 642-649, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-26782928
9.
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
Diabetes Ther
; 14(8): 1415-1425, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256503
10.
IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
Diabetes Ther
; 11(1): 331-339, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31760599
11.
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.
Diabetes Care
; 43(2): 398-404, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31658975
12.
Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
J Diabetes Investig
; 7(4): 574-80, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27181070
13.
Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
J Diabetes Investig
; 7(2): 270-5, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27042281
14.
Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019.
Diabetes Ther
; 11(2): 561-567, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31925723
Resultados
1 -
14
de 14
1
Próxima >
>>